{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-26-000063","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2026-06-18T11:02:51+00:00","discovered_at":"2026-06-18T11:05:00.314963+00:00","generated_at":"2026-06-18T11:05:04.325486+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora reports KIO-300 suppresses seizure activity in preclinical epilepsy model","bullets":["KIO-300 significantly reduced epileptiform event frequency in hippocampal CA1 slices (p<0.0001).","Suppression persisted through treatment and washout; no impairment of normal electrical transmission.","Data presented at Epilepsy Foundation Pipeline Conference, June 18-19, 2026 in Leesburg, VA.","KIO-300 is the active ingredient of KIO-301, currently in Phase 2 for Retinitis Pigmentosa.","CEO cites broad therapeutic potential beyond ophthalmology; full rights retained outside eye."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-26-000063","json":"https://secwatch.observer/filing/0001372514-26-000063.json","markdown":"https://secwatch.observer/filing/0001372514-26-000063.md","text":"https://secwatch.observer/filing/0001372514-26-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/0001372514-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/kprx-20260618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:05:04.325486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}